Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
979
datasets available to search
ShareScore release 0.9.0
Dataset results
979 results for “HR”
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
ClinicalTrials.gov study NCT06849947. IPD Sharing: NO. Countries: 0. Publications: 0.
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT05295043. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study
ClinicalTrials.gov study NCT06495515. IPD Sharing: NO. Countries: 0. Publications: 0.
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Fol
ClinicalTrials.gov study NCT04967248. IPD Sharing: NO. Countries: 0. Publications: 0.
Bone Microstructure by Using HR-pQCT After Esophagectomy
ClinicalTrials.gov study NCT05812235. IPD Sharing: NO. Countries: 0. Publications: 0.
A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
ClinicalTrials.gov study NCT03560856. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
ClinicalTrials.gov study NCT04809584. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer
ClinicalTrials.gov study NCT06605690. IPD Sharing: Not stated. Countries: 0. Publications: 0.
24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
ClinicalTrials.gov study NCT00757835. IPD Sharing: Not stated. Countries: 0. Publications: 0.
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
ClinicalTrials.gov study NCT07307287. IPD Sharing: NO. Countries: 0. Publications: 0.
A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast Cancer
ClinicalTrials.gov study NCT07180914. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
ClinicalTrials.gov study NCT05829434. IPD Sharing: NO. Countries: 0. Publications: 0.
Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
ClinicalTrials.gov study NCT05806047. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT04856371. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT07393321. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT05512416. IPD Sharing: Not stated. Countries: 0. Publications: 0.
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT06470633. IPD Sharing: NO. Countries: 0. Publications: 0.
An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT06613373. IPD Sharing: NO. Countries: 0. Publications: 0.
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
ClinicalTrials.gov study NCT05253066. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
ClinicalTrials.gov study NCT07101159. IPD Sharing: NO. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.